JP6675300B2 - 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 - Google Patents

抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 Download PDF

Info

Publication number
JP6675300B2
JP6675300B2 JP2016502876A JP2016502876A JP6675300B2 JP 6675300 B2 JP6675300 B2 JP 6675300B2 JP 2016502876 A JP2016502876 A JP 2016502876A JP 2016502876 A JP2016502876 A JP 2016502876A JP 6675300 B2 JP6675300 B2 JP 6675300B2
Authority
JP
Japan
Prior art keywords
egfr
egfr gene
copy number
treatment
determined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016502876A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515141A5 (enExample
JP2016515141A (ja
Inventor
チエ ヤン
チエ ヤン
イーヨウ チェン
イーヨウ チェン
ヘンリー チシャン リ
ヘンリー チシャン リ
チエ カイ
チエ カイ
Original Assignee
クラウン バイオサイエンス インコーポレイテッド（タイカン）
クラウン バイオサイエンス インコーポレイテッド（タイカン）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クラウン バイオサイエンス インコーポレイテッド（タイカン）, クラウン バイオサイエンス インコーポレイテッド（タイカン） filed Critical クラウン バイオサイエンス インコーポレイテッド（タイカン）
Publication of JP2016515141A publication Critical patent/JP2016515141A/ja
Publication of JP2016515141A5 publication Critical patent/JP2016515141A5/ja
Application granted granted Critical
Publication of JP6675300B2 publication Critical patent/JP6675300B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2016502876A 2013-03-14 2014-03-14 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 Expired - Fee Related JP6675300B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2013/072638 2013-03-14
PCT/CN2013/072638 WO2014139131A1 (en) 2013-03-14 2013-03-14 Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents
PCT/US2014/028714 WO2014153018A1 (en) 2013-03-14 2014-03-14 Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019202804A Division JP2020040959A (ja) 2013-03-14 2019-11-08 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用

Publications (3)

Publication Number Publication Date
JP2016515141A JP2016515141A (ja) 2016-05-26
JP2016515141A5 JP2016515141A5 (enExample) 2017-04-06
JP6675300B2 true JP6675300B2 (ja) 2020-04-01

Family

ID=51535817

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502876A Expired - Fee Related JP6675300B2 (ja) 2013-03-14 2014-03-14 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用
JP2019202804A Pending JP2020040959A (ja) 2013-03-14 2019-11-08 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019202804A Pending JP2020040959A (ja) 2013-03-14 2019-11-08 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用

Country Status (3)

Country Link
US (1) US10442862B2 (enExample)
JP (2) JP6675300B2 (enExample)
WO (2) WO2014139131A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014139131A1 (en) 2013-03-14 2014-09-18 Crown Bioscience, Inc. Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents
US10484156B2 (en) * 2016-11-16 2019-11-19 Qualcomm Incorporated Search space associated with physical downlink control channel based on channel quality indicators
JP7113842B2 (ja) * 2017-03-29 2022-08-05 クラウン バイオサイエンス，インコーポレイテッド（タイツァン） 胃がんのセツキシマブ感受性を決定するためのシステムおよび方法
WO2018226863A1 (en) * 2017-06-06 2018-12-13 University Of Maryland, College Park Analysis of single cell mechanical phenotyping for metastatic detection
CN107582993A (zh) * 2017-11-10 2018-01-16 兰志英 一种治疗胃癌的药物及其制备方法
CN113164480B (zh) * 2018-11-14 2023-11-28 学校法人金泽医科大学 用于治疗弥漫性胃癌的药物组合物
CN115197320A (zh) * 2021-04-07 2022-10-18 中美冠科生物技术（太仓）有限公司 新型抗cd4抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1751309B1 (en) 2004-05-27 2015-07-22 The Regents of The University of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
AU2006332212B8 (en) * 2006-01-04 2013-05-30 Institut National De La Sante Et De La Recherche Medicale Combination therapy using anti-EGFR and anti-HER2 antibodies
US20090017050A1 (en) * 2007-07-13 2009-01-15 Ventana Medical Systems, Inc. Egfr antigen-binding molecules and uses thereof
EP3216874A1 (en) * 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
US9345767B2 (en) * 2011-05-16 2016-05-24 Taiho Pharmaceutical Co., Ltd. Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and EGFR inhibitor
WO2014139131A1 (en) 2013-03-14 2014-09-18 Crown Bioscience, Inc. Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents

Also Published As

Publication number Publication date
US20160024216A1 (en) 2016-01-28
WO2014153018A1 (en) 2014-09-25
WO2014139131A1 (en) 2014-09-18
JP2020040959A (ja) 2020-03-19
US10442862B2 (en) 2019-10-15
JP2016515141A (ja) 2016-05-26

Similar Documents

Publication Publication Date Title
JP5926487B2 (ja) ＥｒｂＢ療法に耐性である癌を治療するための方法
CA2891609C (en) Method for the prognosis and treatment of cancer metastasis
JP2020040959A (ja) 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用
EP2527460B1 (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
RU2706968C2 (ru) Диагностические способы и композиции для лечения глиобластомы
ES2541925T3 (es) Métodos y composiciones para el uso diagnóstico en pacientes de cáncer
US20210349099A1 (en) Cancer biomarkers and methods of use thereof
CN101175492B (zh) 组蛋白脱乙酰酶抑制剂使癌细胞对表皮生长因子抑制剂敏感
CN107109700A (zh) 用于推导对pd‑1拮抗剂的反应的基因特征生物标志物的系统和方法
JP2018508183A (ja) 化学療法耐性癌を治療及び診断する組成物及び方法
AU2017315459A1 (en) Methods of treating fibroblast growth factor 19-mediated cancers and tumors
HK1216039A1 (zh) 鉴定响应抗癌疗法的可能性升高的患者的方法
JP2019518426A (ja) がんの診断及び治療方法
US20120052079A1 (en) Compositions, Kits, and Methods for Predicting Anti-Cancer Response to Anthracyclines
CN106460067A (zh) 诊断方法和用于治疗成胶质细胞瘤的组合物
WO2010040083A2 (en) Gene expression predictors of chemoresistance
JP2016014671A (ja) 抗癌治療への応答可能性の増大した患者を同定する方法
JP2010508277A (ja) 癌を検出および抑制するための方法
JP2022506463A (ja) ファルネシルトランスフェラーゼ阻害剤でがんを治療する方法
CN105188742A (zh) Egfr生物标志物用于利用抗egfr试剂治疗胃癌的用途
EP2732287B1 (en) Methods of prognosing chronic lymphocytic leukemia
KR20160003646A (ko) 항-egfr 제제에 의해 위암을 치료하기 위한 egfr 바이오마커의 용도
JPWO2017022634A1 (ja) グリオーマの予後、遠隔部再発リスク及び浸潤を判定する方法及びキット並びにグリオーマを処置するための医薬組成物
Boeckx Towards improved treatment of metastatic colorectal cancer: novel insights in tumor sidedness and liquid biopsies
HK1230250A1 (en) Diagnostic methods and compositions for treatment of glioblastoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200310

R150 Certificate of patent or registration of utility model

Ref document number: 6675300

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees